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The initial treatment of lupus nephritis is usually based on a
renal biopsy. Subsequent disease flares, however, are often
treated without the benefit of kidney pathology because
repeat biopsies are infrequent. A noninvasive, real-time
method to assess renal pathology would be useful to adjust
treatment and improve outcome. To develop such a method
we collected urine samples at or close to the time of 64
biopsies from 61 patients with lupus nephritis to identify
potential biomarkers of tubulointerstitial inflammation and
correlated these to biopsy parameters scored by a renal
pathologist using a semiquantitative scale. Linear
discriminant analysis was used to weight variables and
derive composite biomarkers that identified the level
of tubulointerstitial inflammation based on urine
concentrations of monocyte chemotactic protein-1, hepcidin
(a marker of active lupus), and liver fatty acid–binding
protein. The discriminant function that described the most
accurate composite biomarkers included urine monocyte
chemotactic protein-1 and serum creatinine as the
independent variables. This composite had sensitivity,
specificity, positive predictive value, and negative predictive
value of 100, 81, 67, and 100%, respectively. Only 14% of
the biopsies were misclassified. Thus, specific renal
pathologic lesions can be modeled by composite
biomarkers to noninvasively follow and adjust the
treatment of lupus nephritis reflecting renal injury.
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When lupus nephritis (LN) is first diagnosed, treatment is
usually based on kidney biopsy findings. After initial
treatment, however, flares of LN are often treated without
the benefit of kidney pathology because repeat biopsies are
infrequently done. Furthermore, there is presently no way of
knowing how a treatment is affecting kidney injury on a real-
time basis, other than by using the surrogate markers of
proteinuria and kidney function, which have limited clinical
utility.1–4 Repeat biopsies done as a component of clinical
studies have often demonstrated continuing active inflam-
mation and/or the progression of chronic changes such as
glomerulosclerosis and interstitial fibrosis despite the use of
presumably effective therapies.1–6 Although clinically silent,
these lesions predispose to chronic kidney disease and later to
end-stage kidney disease.
A continuous readout of kidney pathology would there-
fore be theoretically helpful in planning and following
therapy for LN, and may allow standard regimens to be
tailored for individual patients based on how their disease
is responding. To this end, the identification of urine
biomarkers that accurately reflect kidney pathology during
LN flare cycles is a clinically relevant goal. Some investiga-
tions have addressed this by looking for urine biomarkers
that distinguish LN from other forms of glomerular disease,
or that can differentiate between classes of LN.7,8 Such
biomarkers, if successfully developed, will reflect an inte-
grated sum of kidney injuries, and thus a broad picture of
renal pathology.
In contrast, our group has approached the discovery of
biomarkers of kidney pathology in systemic lupus erythe-
matosus (SLE) by focusing on biomarkers that reflect distinct
pathologic lesions that are potentially important treatment
targets to prevent chronic kidney disease. This approach is
more specific and flexible than correlating biomarkers with
International Society of Nephrology (ISN)/Renal Pathology
Society (RPS) classes of LN, and potentially more useful, in
that there can be broad variations in the histology within
the same LN class, and combinations of classes are not
infrequent.9–11 Additionally, the ISN/RPS schema does not
address all the compartments of the kidney equally, but
mainly considers glomerular changes. In this context,
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pathology of the renal interstitium is relevant. Inflammatory
injury to the renal interstitium can result in interstitial
fibrosis, and often determines the fate of the kidneys in
LN.1,5,6,12 This report describes the development of a
biomarker of interstitial inflammation in LN.
RESULTS
Biopsy cohorts
Kidney biopsies were done for the clinical diagnosis of
glomerular disease in 61 patients. All biopsies showed
immune complex glomerulonephritis consistent with LN.
The entire biopsy population is described in Table 1. The
patients with moderate–severe interstitial inflammation were
directly compared with the patients with mild or no
interstitial inflammation (Table 2). African Americans and
other non-Caucasians were overrepresented in the moder-
ate–severe inflammation group. Patients with moderate–se-
vere inflammation had significantly more proteinuria at
biopsy than patients with none–mild interstitial inflamma-
tion. Serum creatinine (SCr) was numerically higher at the
time of biopsy in patients with moderate–severe inflamma-
tion, but this did not reach significance. Similarly, there was a
higher, but nonsignificant, proportion of patients with class
IV or IVþV LN in the moderate–severe group.
Candidate biomarkers of interstitial inflammation
In our initial approach, three candidate biomarkers were
selected and examined for correlation with interstitial
inflammation. These biomarkers were urine monocyte
chemoattractant protein-1 (uMCP-1), urine hepcidin (uHep-
cidin), and urine liver-type fatty acid–binding protein
(uLFABP).
uMCP-1 is a biomarker of active LN,13 and MCP-1 is
made by infiltrating interstitial leukocytes in a number of
glomerular diseases.14 As shown in Table 2, uMCP-1 was
significantly greater in patients with moderate–severe inter-
stitial inflammation than patients with mild or no interstitial
inflammation. When used to classify the severity of inter-
stitial inflammation in this test set of biopsies, uMCP-1
misclassified 10 of 64 biopsies (Table 3).
uHepcidin was selected because a nonbiased proteomic
approach showed that it was differentially expressed in the
urine during the evolution of LN flares.15
Immunohistochemical staining demonstrated that infil-
trating interstitial leukocytes expressed hepcidin in LN
kidney biopsies, and human monocytes were shown to
produce hepcidin in response to treatment with interleukin-6
and interferon-a.16 uHepcidin was also significantly in-
creased in patients with moderate–severe interstitial inflam-
mation as compared with patients with mild or no
inflammation (Table 2). When used alone to classify the
severity of interstitial inflammation, uHepcidin misclassified
22 of 64 biopsies (Table 3).
LFABP is made by the proximal tubule in response to
injury,17 and was postulated to be responsive to interstitial
inflammation. It was significantly increased in the urine of
patients with moderate–severe interstitial inflammation
(Table 2). When used alone, uLFABP misclassified 14 of 64
biopsies (Table 3).
Table 3 lists the sensitivity, specificity, and positive and
negative predictive values of each of these individual
biomarkers as predictors of the degree of interstitial
inflammation. uMCP-1 performs fairly well, but uHepcidin
and uLFABP do not. When individual data for each
biomarker were examined, there was considerable overlap
Table 1 | Cohort characteristics
Male/female 11/50
Age (range) 30 (17–51)
African American (%) 26 (43%)
Caucasian (%) 28 (46%)
Other race/ethnicity (Asian, Hispanic, Middle Eastern) 7 (11%)
SLE class at biopsy
2 6
3 9
4 27
5 6
3+5 6
4+5 10
Median urine protein-to-creatinine ratio (range) 2.3 (0.24–16.5)
Median serum creatinine, mg/dl (range) 0.93 (0.38–5.98)
Median prednisone dose at urine collection, mg/day
(range)
17.5 (0–60)
Median MMF dose at urine collection, g/day (range) 0 (0–3000)
Median AZA dose at urine collection, mg/day (range) 0 (0–150)
Pulse corticosteroids given before urine collection
(% patients)
12 (19%)
Abbreviations: AZA, azathioprine; MMF, mycophenolate mofetil; SLE, systemic lupus
erythematosus.
Table 2 | Comparison of patients with different levels of
interstitial inflammation
Demographic/clinical feature/
biomarker level
None–mild
inflammation
Moderate–severe
inflammation
Caucasian (%) 25 (53) 4 (24)
African American (%) 16 (34) 11 (64)a
Other (%) 6 (13) 2 (12)a
Age 30±1.1 32±2.1
Mean SCrb (mg/dl) 1.09±0.10 2.61±0.37
Mean uPCR 2.80±0.42 5.33±1.23c
Class II (%) 6 (13%) 0
Class III, III+V (%) 11 (23%) 4 (23.5%)
Class IV, IV+V (%) 25 (53%) 12 (70.5%)
Class V (%) 5 (11%) 1 (6%)
uMCP-1 (ng per mg Cr) 1.22±0.15 5.21±1.18d
uHepcidin (ng per mg Cr) 235±55 658±229e
uLFABP (ng per mg Cr) 71±10 152±31f
Abbreviations: Cr, creatinine; SCr, serum creatinine; uHepcidin, urine hepcidin;
uLFABP, urine liver-type fatty acid–binding protein; uMCP-1, urine monocyte
chemoattractant protein-1; uPCR, urine protein/creatinine ratio.
aAfrican Americans plus other races/ethnicities were significantly overrepresented in
the moderate–severe interstitial inflammation group (P=0.048, Fisher’s exact test).
bSCr±s.e.m.
cPo0.0001 versus none–mild inflammation (Mann–Whitney test).
dBiomarker levels are mean±s.e.m.; Po0.0001 versus none–mild inflammation
(Mann–Whitney test).
ePo0.003 versus none–mild inflammation (Mann–Whitney test).
fPo0.002 versus none–mild inflammation (Mann–Whitney test).
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of values in patients with mild or no inflammation and
patients with moderate–severe inflammation (data not
shown). This contributes to misclassifications and poor
performance characteristics.
Combining urine and clinical biomarkers
We next determined if the performance characteristics to
differentiate interstitial inflammation status could be im-
proved, and misclassifications could be attenuated by
combining candidate urine biomarkers and clinical biomark-
ers. All combinations of uMCP-1, uHepcidin, uLFABP, SCr,
and proteinuria (expressed as urine protein/creatinine ratio
(uPCR)) were tested by linear discriminant analysis, a
procedure that produces optimal weights for the log-
transformed variables involved. The linear discriminant
analysis was based on the 49 urine samples collected at the
time of biopsy and did not include any repeat biopsies. The
best resulting combination is given below:
Y1 ¼ 0:992  lnðuMCP 1Þ þ 2:213  ln ðScrÞ ð1Þ
Here, Y1 is the linear discriminant score, and the Y1 value that
gave the maximum sum of sensitivity and specificity is 1. At
and above this cutoff, biopsies were assigned to moderate–-
severe interstitial inflammation and below this cutoff,
biopsies were assigned to none–mild interstitial inflamma-
tion. The same threshold value of 1 gave the best sum of
sensitivity and specificity when applied to all 64 subjects and
had the least misclassification probability (Table 3). With this
linear discriminant score, only 9 of 64 biopsies (14%) were
misclassified, specificity was 81%, and sensitivity was 100%
(Table 3). This means that all misclassifications were from
none–mild to moderate–severe inflammation. No cases of
moderate–severe interstitial disease were misclassified. The
positive predictive value was 67% and the negative predictive
value was 100%. The receiver operating characteristic curve
for this composite biomarker is shown in Figure 1. The area
under the curve was 0.92.
For comparison, all 5 variables were used to derive a
biomarker from the same 49 cases. This composite biomarker
had lower specificity and a higher number (11) of
misclassified cases than Y1.
The misclassified patients could not be differentiated from
correctly classified patients by the use of medications at the
time of biopsy, including pulse methylprednisolone, oral
corticosteroids, or immunosuppressive drugs. Two misclassi-
fied patients received pulse methylprednisolone (22%),
whereas 10 correctly classified patients received pulse
corticosteroids (18%). The median dose of prednisone in
the misclassified patients was 3mg/day (range 0–60), and in
the correctly classified patients it was 20mg/day (range 0–60).
Additionally, the misclassified patients could not be differ-
entiated from correctly classified patients by the timing of
their urine samples as only two patients gave urine samples
after their biopsies. Interestingly, all misclassified patients
had an elevated SCr, and their average creatinine was
significantly greater than the correctly classified patients
(2.24±0.28 vs. 1.37±0.16mg/dl, P¼ 0.003). It is not likely
that this finding can be used to identify patients who are
likely to be misclassified as several correctly classified patients
had SCr values in this range or higher.
Table 3 | Performance characteristics of biomarkers of interstitial inflammation for all biopsiesa
Biomarker Threshold valueb Misclassifications (%) Sens. (%) Spec. (%) PPV (%) NPV (%) AUC under ROC
uMCP-1 2.2 10/64 (16) 83 85 67 93 0.87
uLFABP 118 14/64 (22) 65 83 58 87 0.75
uHepcidin 136.5 22/64 (34) 83 60 42 90 0.70
uPCR 3.7 18/61 (30) 56 76 45 83 0.65
SCr 1.43 13/64 (20) 83 79 58 93 0.86
Equation (1) Y1 (applied to all biopsies) 1 9/64 (14) 100 81 67 100 0.92
Equation (1) Y1 (applied to 49 biopsies) 1 6/49 (12) 100 83 68 100 0.91
Abbreviations: AUC, area under the curve; NPV, negative predictive value; PPV, positive predictive value; ROC, receiver operating characteristic; SCr, serum creatinine; Sens.,
sensitivity; Spec., specificity; uHepcidin, urine hepcidin; uLFABP, urine liver-type fatty acid–binding protein; uMCP-1, urine monocyte chemoattractant protein-1; uPCR, urine
protein/creatinine ratio.
aThresholds and models developed from the 49 cases taken at biopsy, and excluded repeat biopsies. Thresholds were chosen to maximize the observed sum of sensitivity and
specificity for the associated biomarker.
bWith this value or greater classify as moderate–severe interstitial inflammation.
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Figure 1 |Receiver operating characteristic (ROC) curve for a
composite biomarker of renal interstitial inflammation. This
ROC curve is based on Equation (1) that combines urine monocyte
chemoattractant protein-1 (uMCP-1) and serum creatinine (SCr) to
differentiate biopsies with none–mild interstitial inflammation
from moderate–severe interstitial inflammation. The area under
the curve (AUC) is 0.92.
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A biomarker for interstitial fibrosis
We next determined if the urine and clinical biomarkers
could be combined to yield a linear discriminant equation for
interstitial fibrosis. This seemed possible, as interstitial
inflammation leads to injury that may result in interstitial
fibrosis and chronic kidney disease.1,5,6,12 The ability to
classify interstitial fibrosis as moderate–severe or none–mild
was examined using discriminators based on urines obtained
at biopsy (no repeat biopsies). For fibrosis, the best
discriminant function is given by Equation (2) with a
threshold value of 1:
Y2 ¼ 4:177  lnðuPCRÞ  1:425  lnðuHEPÞ ð2Þ
The performance characteristics of individual biomarkers
and the combined biomarker Y2 are given in Table 4 for all
biopsies.
The combined biomarker Y2 threshold of 1 based on 46
biopsies did not produce the best sum of sensitivity and
specificity for all 60 biopsies, but yielded the lowest
misclassification proportion. The best sum of sensitivity
and specificity was achieved with a threshold value of 2.94
(sensitivity 80%; specificity 62%) but misclassified 20 out of
61 cases (or 33%). However, the difference in the sum of
sensitivity and specificity is just 2%. The threshold Y2 value
of 1 was thus favored given the lower rate of misclassifica-
tion. The receiver operating characteristic curve for this
composite biomarker is shown in Figure 2. The area under
the curve was 0.74.
Application to other kidney diseases
The interstitial inflammation biomarker Equation (1) was
applied to 10 biopsies that were not LN. These biopsies
included an idiopathic immune complex glomerulonephritis
(1), pauci-immune necrotizing and crescentic glomerulone-
phritis (1), membranous glomerulopathy (1), diabetic
glomerulosclerosis (1), IgA nephropathy (1), advanced
chronic kidney disease (1), glomerular basement membrane
abnormalities (2), and nonspecific findings (2). Only one of
these biopsies had moderate–severe interstitial inflammation,
and the rest had none–mild interstitial inflammation.
Equation (1) correctly classified 8 of the 10 biopsies,
including the biopsy with severe interstitial inflammation.
Two biopsies with none–mild interstitial inflammation were
misclassified as moderate–severe, and similar to the mis-
classified LN patients described previously, these patients had
elevated SCr levels.
DISCUSSION
The ability to noninvasively follow changes in kidney
pathology during the treatment of LN would be an important
step forward in improving disease management and out-
come. Here we have demonstrated that a composite
biomarker, uMCP-1þ SCr, accurately reflects renal inter-
stitial inflammation in a moderately sized cohort of SLE
patients. Although individual candidate urine biomarkers
were, on average, differentially expressed relative to the level
of interstitial inflammation in a population, there was
significant overlap among cases with and without interstitial
inflammation, and this attenuated the performance of single
urine proteins as biomarkers.
Table 4 | Performance characteristics of biomarkers of interstitial fibrosis for all biopsiesa
Biomarker Threshold valueb Misclassifications (%) Sens. (%) Spec. (%) PPV (%) NPV (%) AUC under ROC
uMCP-1 1.51 25/63 (40) 65 59 37 80 0.66
uLFABP 148 17/63 (27) 41 85 50 80 0.60
uHepcidin 32.5 14/63 (22) 35 93 67 80 0.48
uPCR 4.0 13/60 (22) 67 80 56 88 0.72
SCr 0.81 26/63 (41) 94 46 39 95 0.75
Equation (2) Y2 (applied to all biopsies) 1 13/60 (22)c 53 87 57 85 0.74
Equation (2) Y2 (applied to 46 biopsies) 1 8/46 (17) 64 89 64 88 0.76
Abbreviations: AUC, area under the curve; NPV, negative predictive value; PPV, positive predictive value; ROC, receiver operating characteristic; SCr, serum creatinine; Sens.,
sensitivity; Spec., specificity; uHepcidin, urine hepcidin; uLFABP, urine liver-type fatty acid–binding protein; uMCP-1, urine monocyte chemoattractant protein-1; uPCR, urine
protein/creatinine ratio.
aThresholds and models developed from the 46 cases taken at biopsy, and excluded repeat biopsies. Thresholds were chosen to maximize the observed sum of sensitivity and
specificity for the associated biomarker. Note that in this set there are 46 cases instead of 49 as in Table 3 because 3 cases had missing uPCR.
bWith this value or greater classify as moderate–severe interstitial fibrosis.
cThere are 60 biopsies here instead of 64 as in Table 3 because of missing uPCR in 4 cases.
1
0.8
0.6
0.4
Tr
u
e
 p
os
itiv
e
 (s
en
sit
ivi
ty)
0.2
0
False positive (1-specificity)
AUC = 0.74
0 0.2 0.4 0.6 0.8 1
Figure 2 |Receiver operating characteristic (ROC) curve for a
composite biomarker of renal interstitial fibrosis. This ROC
curve is based on Equation (2) that combines urine hepcidin
(uHep) and urine protein/creatinine ratio (uPCR) to differentiate
biopsies with none–mild interstitial fibrosis from moderate–severe
interstitial fibrosis. The area under the curve (AUC) is 0.74.
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Equation (1) misclassified 14% of the biopsies. With
additional training data this rate may become lower, but will
likely not go to zero. Although the kidney biopsy is the gold-
standard comparator for Equation (1), there is a finite rate of
misclassification with tissue readings. The accuracy of a
kidney biopsy depends on the size of the tissue sample
obtained. For example, the correct diagnosis of glomerular
disease or kidney allograft rejection requires an adequate
biopsy defined by a minimum number of glomeruli and
blood vessels.18,19 There is no information on correct
classification of tubulointerstitial lesions by biopsy in SLE;
however, in a study of paired kidney transplant biopsies,
interstitial fibrosis identified on the first biopsy was not seen
in 12% of second biopsies.20 Because it was not felt that
regression of fibrosis had occurred, this was thought to be an
estimate of misclassification of tubulointerstitial disease by
biopsy, and is close to that of our composite biomarker. It is
conceivable that urine biomarkers could be less likely to
misclassify kidney pathology because they reflect the total
renal environment and are not subject to biopsy sampling
errors and size variations.
Although this biomarker of interstitial inflammation was
developed for the evaluation of LN, it is likely that it can be
used to describe the renal interstitium in other types of
kidney disease. Although this will need to be tested in a larger
group of non-lupus patients than included here, it is relevant
because tubulointerstitial injury, including interstitial in-
flammation and fibrosis, is a risk factor for renal functional
decline and poor response to therapy in a variety of
disorders. These include membranous nephropathy, focal
segmental glomerulosclerosis, IgA nephropathy, diabetic
nephropathy, and renal transplant failure.21–27 Similar to
LN, interstitial inflammation appears to be a precursor to
interstitial fibrosis in these diseases.27
Given the relationship between interstitial inflammation
and interstitial fibrosis, we used uMCP-1, uLFABP, uHepci-
din, uPCR, and SCr to derive a composite biomarker of renal
interstitial fibrosis. Here uPCR and uHepcidin were in-
formative, but the composite biomarker did not perform as
well as Equation (1), suggesting that addition of other
component markers is needed for a final composite fibrosis
biomarker.
Our markers of interstitial inflammation and fibrosis were
derived from biopsies read for clinical use. Thus, the markers
were based on a semiquantitative evaluation of interstitial
inflammation and fibrosis, rather than precise morphometric
measurements and enumeration of individual subtypes of
interstitial leukocytes. Reassessment of interstitial inflamma-
tion and fibrosis in a more quantitative fashion may further
improve biomarker models.
The misclassification of biopsies did not appear to be
because of increased use of corticosteroids or immunosup-
pressive medications, or a delay in the collection of urine
after biopsy in the misclassified patients.
In summary, this pilot work demonstrates that combina-
tions of urine proteins and clinical variables can be used to
derive potentially useful composite biomarkers that reflect
specific pathologic lesions in the kidneys of patients with LN.
A limitation of our study is the relatively modest sample size
of LN biopsies used for linear discriminant analysis. With
larger test sets and more precise (quantitative) measurements
of pathology, we expect these biomarker equations can be
more finely tuned to increase accuracy. Another important
limitation is that we do not have an independent set of LN
biopsies to use as a validation cohort. This will be necessary
before the biomarkers can be used clinically. Despite these
limitations, it is envisioned that eventually these biomarkers
will be used to follow patients with LN and possibly other
forms of kidney disease over time, and individualize
treatment decisions.
MATERIALS AND METHODS
Kidney biopsy cohort
The cohort comprised 64 kidney biopsies from 61 patients, all of
whom had at least 4 American College of Rheumatology criteria for
SLE, including immune complex glomerulonephritis, and many of
whom participated in the Ohio SLE Study.28 Three patients had
repeat biopsies. Urine was collected on the day of biopsy or within
24 h, except in 12 cases where urine was collected within 2 (n¼ 4),
3 (n¼ 2), 4, 6, 7 (n¼ 2), 12, and 13 days of kidney biopsy. After
urine was collected it was centrifuged to remove sediment and
stored in preservative-free aliquots at 80 1C until use.
Measurement of interstitial inflammation and fibrosis in
kidney biopsies
Interstitial inflammation and interstitial fibrosis were semi-
quantitatively graded as none, mild, moderate, or severe on
light-microscopic sections for clinical biopsy reports by a nephro-
pathologist blinded to urine biomarker data. The stains used to
estimate the percentage of involved cortex were hematoxylin and
eosin, periodic acid–Schiff, and tri-chrome. None was considered to
be up to 5% of the renal interstitium; mild between 6 and 25%,
moderate between 26 and 50%, and severe 450%.1,29 For analysis,
biopsies with none–mild inflammation were combined, and biopsies
with moderate and severe fibrosis were combined. The rationale for
this grouping was to model and distinguish clinically significant
interstitial disease, as has been shown in previous studies.1,30
Measurement of urine biomarkers
Urine MCP-1 levels were measured using the Quantikine Human
CCL2/MCP-1 ELISA kit from R&D Systems (Minneapolis, MN) as
described before.13 uMCP-1 was normalized to urine creatinine.
Creatinine was measured with a Creatinine Detection Kit (Assay
Designs, Ann Arbor, MI). The final values were expressed as ng
MCP-1 per mg creatinine.
The uLFABP level was measured using the Human L-FABP
ELISA kit from CMIC (Tokyo, Japan) following the manufacture’s
protocol and uLFABP was corrected by urine creatinine. The final
values were expressed as ng L-FABP per mg creatinine.
Hepcidin-25 was measured by EIA (Bachem Group, Torrance,
CA) as described before.16 The hepcidin-25 standard liver-expressed
antimicrobial peptide 1 (LEAP1) from Peptides International
(Louisville, KY) was used to validate this EIA. The R2 value was
0.9967 for LEAP1 from 0 to 50 ng/ml using sigmoid regression. The
coefficient of variation for a fixed hepcidin-25 concentration of
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1.56 ng/ml was 3.49% intra-assay and 3.43% interassay. Urine
hepcidin was then normalized to urine creatinine with the final
value expressed as ng hepcidin per mg creatinine.
Data analysis
Fisher’s linear discriminant analysis was used to determine the
discriminant score function based on one or more normally
distributed components. This procedure produces an optimally
weighted linear function of the chosen log-transformed markers and
the discriminating threshold value minimizes the expected number
of misclassifications under the normal model. This does not
necessarily maximize the sum of sensitivity and specificity. We
modified the threshold value to be the one that maximizes this sum
for the observed data. The data were log transformed because we
examined the Box–Cox family of transformations to look for a good
fit to normality and it resulted in the choice of log transformation.
The Shapiro–Wilk test was used to formally test for normality of the
log-transformed variables. It showed an excellent fit for uMCP-1,
uHepcidin, and uPCR, and a moderate fit for SCr, where a slight
positive skewness was noticed. For uLFABP, the data were bimodal
for the none–mild inflammation group and normal for the
moderate–severe group. The software used for analysis was SAS
JMP 9.0 (Cary, NC). Comparisons of two groups were done using
the Mann–Whitney test. A two-tailed Po0.05 was considered
significant.
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